Safety Study of Rituximab (Rituxan®) in Chronic Urticaria
Stopped early · Phase 1/Phase 2
Conditions studied: Urticaria
In brief
This study is being done to find out if a drug called Rituxan (Rituximab) is safe and effective in treating people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.
Key facts
- Study ID
- NCT00216762
- Run by
- Johns Hopkins University
- People needed
- 15
- Starts
- 2006-01-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2015-09-02
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Johns Hopkins University, Bayview Medical Center — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.